The Expert Angle
Medlior is a well-known and trusted industry leader.
Our team is dedicated to delivering high-quality research that provides a solid basis for informed decision-making.
Medlior’s Expert Angle offers the inside track on new studies, industry hot topics, and what you need to know in the fast-paced world of clinical research, all from the point of view of the Medlior team of experts. From the latest topics and trends to the foundations of health and medical research, Medlior explores topics relevant to clients and the world.
CADTH RWE Framework
I had the pleasure of attending the The Canadian Association for Population Therapeutics annual conference in Toronto, Canada. The program was titled “Embracing Change and Uncertainty to Improve the Health of Canadians” and it was kicked-off with a townhall session on Canadian RWE Initiatives...
World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases Presentations: Trends in Osteoporotic Incidences and Care during the COVID-19 Pandemic
A real-world evidence study examining COVID-19 pandemic disruptions in osteoporosis care patterns and outcomes across Alberta, Canada, was presented through two posters at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
Early Diagnosis of Alzheimer’s Disease Using AI Techniques in Primary Care
Alzheimer’s disease (AD) is a degenerative neurological disease with progressive death of brain cells, eventually leading to death.1,2 It is the most prevalent irreversible dementia, marked by deterioration of memory, judgement, and reasoning and worsening of mood, behaviour, communication, and function to perform daily activities.1 With longer life expectancy and an aging population, the burden of AD on the quality of life of patients and their family and caregivers is increasing.
Indigenous healthcare research in Canada—A changing landscape
With National Indigenous People’s Day on June 21st, Medlior is reflecting on health disparities for Indigenous peoples in Canada. First Nations, Inuit, and Métis people have typically been underrepresented in research studies, but there are promising signs of change.
Canada’s Rare Disease Strategy – What is it and why do we care?
Approximately 1 in 12 Canadians, mostly children, are affected by a rare disorder. Patients with rare diseases face many challenges, including misdiagnosis, limited treatment, and difficulty accessing innovative therapies even when they are available. Implementing the Rare Disease Strategy will not necessarily cost Canadians more. Earlier diagnosis and correct treatments can lead to reduced unnecessary surgeries, organ transplants, and visits to multiple specialists, resulting in savings for the health system and taxpayers.
Value-based Health Care
Reflecting over the last 2 years
The pandemic has shown us the crucial imperative of having highly functioning and interconnected healthcare systems. Everything comes at a cost which is why it is so important to achieve the greatest value for money. But what is value and whose values matter ...
Looking Forward To 2022
Following the unprecedented year of 2020, 2021 brought increased global awareness to our field of work. The pandemic has brought terms such as ‘epidemiology’, ‘efficacy’ and ‘real word evidence’ into lay language and the vital role of health outcomes research has become increasingly apparent. ...
Looking Back On 2021
As the reality of living amongst a global pandemic set in across the world over the past year, a key highlight of 2021 was undoubtedly the rollout of life saving vaccines from AstraZeneca, Pfizer, Johnson and Johnson, and Moderna.
At Medlior, this was also a year of continued ...
Trends in major adverse cardiac events during the COVID-19 pandemic in Alberta, Canada
Dr. Shaun Goodman, from the Division of Cardiology, St. Michael's Hospital, Toronto, Ontario, and Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, presented a poster at the 2021 Scientific Sessions American Heart Association Virtual Conference focusing on trends in major ...
Disease Burden of Huntington’s Disease in a Canadian Setting Using Administrative Health Data
A real-world evidence study focusing on the burden of Huntington’s disease (HD) in Alberta, was presented at the virtual 28thAnnual Meeting of the Huntington Study Group (HSG) from November 4-6, 2021. This study was conducted by Medlior on behalf of Hoffmann-La Roche. A background on ...
Virtual Canadian Congress of Cardiology Presentation: COVID-19 Pandemic Induced Disruptions in Troponin and Low-Density Lipoprotein Cholesterol Laboratory Test Volumes Across Alberta
On March 11, 2020, the World Health Organization made the announcement that the coronavirus-2019 (COVID-19) was officially characterized as a pandemic.1 As many healthcare resources were redeployed or redistributed to address the acute need of COVID-19, large impacts on health systems were ...
Virtual ISPOR 2021: Burden of Disease and Current Treatment Patterns for Migraine in Canada
E-Poster Title: Epidemiology, Treatment Landscape, and Healthcare Resource Utilization for Patients with Migraine in Canada
Migraine is a common, debilitating headache disorder that is the third leading cause of global disability and the leading cause of years lived with disability (YLDs) ...
